Basel, Switzerland – 10 Feb, 2025, Phialogics AG has announced the appointment of Dr. Natalia Novac as Chief Executive Officer.
Natalia has a great experience in holding executive and board positions in several biotech startups. She was a Partner, responsible for life sciences at Delin Ventures and a part of Eli Lilly venture science team where she was responsible for corporate interactions with a number of venture funds as well as for search and evaluation of novel technologies across all five indications of Eli Lilly: oncology, immunology, neurodegeneration, diabetes and pain. Prior to Lilly, Natalia was working in Merck KGaA for over a decade, starting as a scientist in early discovery high throughput screening, through knowledge management consultancy to development projects and driving cultural program, to launching PDL-1 inhibitor as a Head of Strategy in the UK and Ireland. Natalia’s first degree is in biochemistry, second in microbiology and she has a PhD in molecular oncology.
”Over the last 2 years, we, at Phialogics, have made tremendous progress in science and have proved the unique value of our technology to address autoimmune disease. We have also raised quite a strong level of interest among the investment community. I‘m pleased to have Natalia join us as CEO to move the company to the next step. Her vast knowledge of the ecosystem will be instrumental in reaching the next company milestones!
Andreas ErnstChief Scientific Officer at Phialogic
”I am really honored to join Phialogics, embarking on an exciting journey with a passionate and dedicated team. Together we aim to make meaningful strides in advancing innovative therapies for autoimmune diseases delivering life-changing treatments for patients. I look forward to leveraging my experience and working alongside this impressive team of scientists and investors to drive the company’s success.
Dr. Natalia NovacChief Executive Officer at Phialogics
About Phialogics
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.
We are thrilled to welcome Natalia and wish the whole team a great success!
